I-Mab

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.

GAITHERSBURG, MD. and SHANGHAI, China , Oct. 5, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will present new preclinical data of its core assets lemzoparlimab and uliledlimab, respectively, at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, as well as virtually November 8-12, 2022.

I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022

Clearance from China was received to initiate a phase 3 registrational study using Lemzoparlimab for high-risk MDS patients; trial initiation is expected in Q4 of 2022. Results from phase 2 studies using uliledlimab for the treatment of patients with non-small cell lung cancer are expected in Q4 of 2022.

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

Los Angeles, California--(Newsfile Corp. - September 19, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I-Mab ("I-Mab" or "the Company") (NASDAQ: IMAB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - September 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether I-Mab and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of I-Mab - IMAB

GAITHERSBURG, Md. and SHANGHAI , Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting with the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), and has obtained approval from the CDE to initiate a Phase 3 registrational trial evaluating lemzoparlimab, a novel CD47 antibody, in combination with azacitidine (AZA) for the first-line treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40% Lemzoparlimab does not require priming dosing with no unexpected safety signals in combination therapy with AZA For subjects achieving CR, remaining gene mutation frequency such as TP53, TET2 and RUNX1 were significantly decreased A randomized Phase 3 trial in higher-risk MDS is planned GAITHERSBURG, Md. and SHANGHAI , Sept.

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

Los Angeles, California--(Newsfile Corp. - September 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I-Mab ("I-Mab" or "the Company") (NASDAQ: IMAB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm

Abstract summarizing lemzoparlimab Phase 2 data selected for proffered paper presentation on September 10 Investor conference call scheduled at 8:00 a.m. ET (English) on September 12 GAITHERSBURG, Md.

I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

Los Angeles, California--(Newsfile Corp. - September 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I-Mab ("I-Mab" or "the Company") (NASDAQ: IMAB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - September 2, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I-Mab ("I-Mab" or "the Company") (NASDAQ: IMAB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - September 1, 2022) - Pomerantz LLP is investigating claims on behalf of investors of I-Mab (NASDAQ: IMAB) ("I-Mab" or the "Company"). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether I-Mab and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

I-Mab (NASDAQ:IMAB ) H1 2022 Earnings Conference Call August 30, 2022 9:15 AM ET Company Participants Tyler Ehler – Senior Director of Investor Relations Jingwu Zang – Founder, Chairman and Acting Chief Executive Officer Andrew Zhu – President John Long – Chief Financial Officer Conference Call Participants Kelly Shi – Jefferies Andres Maldonado – H.C. Wainwright Albert Lowe – Piper Tyler Ehler This is Tyler Ehler, I-Mab's Senior Director of Investor Relations.

I-Mab (IMAB) H1 2022 Earnings Call Transcript

Seven key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab, and TJ-CD4B Lemzoparlimab is on track for Phase 3 study for 1L MDS Amendment to the global partnership with AbbVie for certain new CD47 antibodies currently in development with up to US$1.295 billion in milestone payments Significant progress made on the expanded uliledlimab phase 2 NSCLC clinical trial with more complete dataset to be expected Continued focus on key value drivers of five clinical-stage assets with three potential BLAs within the next three years Repositioned commercialization strategy for felzartamab and eftansomatropin alfa Total cash position of US$586 million (RMB3.9 billion), sufficient to fund key business operations for more than three years I-Mab will host conference calls and webcasts on August 30, 2022. A Mandarin session will be held at 7:00 a.m.

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022

GAITHERSBURG, Md. and SHANGHAI , Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it plans to implement share repurchases pursuant to the share repurchase program previously authorized by its Board of Directors.

I-Mab Announces Share Purchase Plans by the Company and the Senior Management

-  M ajor updates will focus on global clinical development of core assets, upcoming milestones and financial results -  The Company will update on potential implementation of a comprehensive share purchase program by the Company and current shareholders -  Conference Calls Scheduled at 7:00 a.m. ET (Mandarin) and 8:15 a.m.

I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022

I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.

I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal

GAITHERSBURG, Md. and SHANGHAI , July 22, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in China has been treated with TJ-CD4B (also known as ABL111), a novel Claudin 18.2 x 4-1BB bispecific antibody, in a Phase 1 international multi-center clinical trial (IMCT) for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal carcinoma (NCT04900818).

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China

GAITHERSBURG, Md. and SHANGHAI , July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data from a Phase 2 study of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with higher risk myelodysplastic syndrome (HR-MDS) will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9 – 13, 2022.

I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

GAITHERSBURG, MD. and SHANGHAI , July 6, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will host its 2022 Research and Development (R&D) Day on July 20, 2022.

I-Mab to Host 2022 R&D Day

The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry.

I-Mab Valuation Offers A Biotech Investment Opportunity

GAITHERSBURG, Md. and SHANGHAI , June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies in five different categories by leading global financial publication Institutional Investor, based on its 2022 All-Asia Executive Team survey.

I-Mab Receives Top Rankings in Five Categories by Institutional Investor

Morphosys AG - ADR

SHANGHAI and GAITHERSBURG, Md. , June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner MorphoSys AG (FSE: MOR; NASDAQ: MOR), felzartamab (also known as TJ202/MOR202) and TJ210 (also known as MOR210), are advancing globally through new license agreements.

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that its partner, I-Mab (Nasdaq: IMAB), recently completed patient enrollment in a phase 3 clinical trial of its proprietary long-acting growth hormone, eftansomatropin alfa, also known as GX-H9/TJ101, in China, taking it one step closer to commercializati

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

SHANGHAI and GAITHERSBURG, Md. , May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinical trial (TALLER) of highly differentiated long-acting recombinant human growth hormone eftansomatropin alfa (also known as TJ101), which is being investigated as a weekly treatment for pediatric growth hormone deficiency (PGHD) in China.

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency

-  Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity -  Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort -  Results indicate CD73 expression correlates with clinical response as a potential predictive biomarker -  Company aims to initiate Phase 3 study in NSCLC in 2023 -  The Company will host investors call on Friday, May 27 at 8 a.m. ET SHANGHAI and GAITHERSBURG, MD.

News for I-Mab Stock (IMAB)